(Q33850678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

A Gawlinski

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

10A-17A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

The value of lowering cholesterol after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Lipid lowering versus revascularization: an idea whose time (for testing) has come

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

A case-management system for coronary risk factor modification after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900933-9

10.1016/S0002-9149(99)00933-9

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10695702%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference